# KLOW Peptide — Angiogenesis-Vascular Research Record: Four Components Dimensioned

> KLOW peptide is a four-component research blend — KPV, GHK-Cu, BPC-157 and TB-500 — with angiogenic and tissue-repair data summarized by component from the peer-reviewed literature.

KPV, GHK-Cu, BPC-157 and TB-500 — four chemically distinct peptides co-formulated in one research vial. Component-attributed evidence only. The blank dimension where a blend trial belongs is drawn in plain view.

## In plain English

KLOW peptide is a research blend of four separate compounds — KPV, GHK-Cu, BPC-157 and TB-500 — dissolved together in one vial. Each ingredient has its own body of laboratory research, mostly in animal models, addressing different aspects of tissue repair, inflammation and blood-vessel growth (called angiogenesis). None of the four components is FDA-approved for human use. The blend itself has never been tested in a controlled study — every benefit attributed to KLOW is an extrapolation from single-component research, not a finding about the combination. The four components occupy different nodes of the tissue-repair process: KPV quiets inflammation, GHK-Cu drives collagen and matrix repair while supplying copper, BPC-157 activates the VEGFR2 angiogenic pathway (the same pathway that triggers new blood-vessel growth), and TB-500 works on the actin cytoskeleton to move cells into wounds. What the research has found for each component — and what people in the research-use community report about the blend — is on the [KLOW effects](/effects) page, including the downsides.

## What is KLOW peptide

KLOW peptide is a co-formulated, lyophilized research blend of four chemically distinct peptides supplied at fixed mass ratios in a single vial. The most widely cited composition across independent compounders is 80 mg total — GHK-Cu (glycyl-L-histidyl-L-lysine copper(II) complex, a copper-chelated tripeptide) 50 mg, BPC-157 (Body Protection Compound 157, a synthetic 15-amino-acid gastric-derived peptide) 10 mg, TB-500 (a synthetic N-acetylated heptapeptide corresponding to the LKKTET actin-binding motif of thymosin beta-4) 10 mg, and KPV (lysine-proline-valine, the C-terminal tripeptide of alpha-MSH) 10 mg. The four peptides do NOT form a single chemical complex — they remain discrete molecules within the co-formulation. No FDA-approved or pharmacopeial KLOW product exists; it is a research-only co-formulation. KLOW is not a GLP-1 agonist, an incretin mimetic, or a weight-management compound. Its research rationale is entirely in tissue repair and inflammation.

## KLOW peptide blend

The combination rationale for the KLOW peptide blend is that the four arms address consecutive and partly overlapping steps of the same repair cascade: cytokine suppression (KPV), matrix synthesis and copper-mediated crosslinking (GHK-Cu), angiogenic vascularization (BPC-157), and cytoskeletal motility to close the wound (TB-500). The angiogenesis-vascular axis — the focus of this site — links the BPC-157 VEGFR2/PI3K/Akt/eNOS pathway [8], GHK-Cu–derived angiogenic peptides from SPARC proteolysis [11], and thymosin beta-4–mediated vascular repair [9] into one overlapping network. The KLOW blend draws those three convergent angiogenic mechanisms onto a single formulation plate. What must be dimensioned honestly: no controlled study has ever tested this blend in any species; the pharmacokinetic half-lives of the four components are markedly different, making matched exposures from one vial a theoretical problem; and the TB-500 fragment's own data are much thinner than the well-studied full-length thymosin beta-4 protein. The combination claim rests entirely on component-level mechanistic extrapolation.

## KLOW

KLOW is distinct from two closely related research blends: GLOW (which contains GHK-Cu, BPC-157 and TB-500 but not KPV) and WOLVERINE (a different composition). The addition of KPV is the defining structural difference between KLOW and GLOW. KPV — the tripeptide Lys-Pro-Val — is the C-terminal three-residue segment of alpha-melanocyte-stimulating hormone (alpha-MSH). It suppresses NF-kappaB (nuclear factor kappa B, a master inflammatory transcription switch) nuclear import in epithelial and immune cells, reduces the pro-inflammatory cytokines TNF-alpha, IL-6 and IL-1beta in vitro, and is transported into inflamed gut epithelium and macrophages by the PepT1 (SLC15A1) di/tripeptide transporter at a Km of approximately 160 microM [3]. KLOW's anti-inflammatory claim rests disproportionately on the KPV literature; GLOW lacks that arm entirely. The [klow stack](/blend-components) page compares the components in full.

## The angiogenesis-vascular axis across the four components

The three pro-angiogenic components in KLOW operate via distinct but converging molecular routes. In BPC-157 studies, the peptide upregulates VEGFR2 (vascular endothelial growth factor receptor 2) expression, promotes VEGFR2 internalization, and activates the downstream PI3K/Akt/eNOS (phosphoinositide-3-kinase / protein kinase B / endothelial nitric-oxide synthase) cascade, increasing vessel density in vivo and accelerating blood-flow recovery in rat hindlimb ischemia models [8]. In the GHK-Cu literature, proteolysis of SPARC (secreted protein acidic and rich in cysteine, also called osteonectin) releases copper-binding peptides including GHK and the more potent KGHK that directly stimulate angiogenesis in endothelial cell and in vivo assays; this identifies an endogenous route by which the tripeptide participates in vascular biology independent of exogenous application [11]. In thymosin beta-4 research (the TB-500 arm draws on this lineage), the native protein promotes angiogenesis, wound healing and hair-follicle development concurrently in rodent models [9]. In a 2025 study, thymosin beta-4–loaded exosome hydrogel improved vascularized wound repair [14]. Across all three arms, the signaling commonality is new-vessel formation supporting tissue perfusion; the components approach it from different receptor systems and different cell types. For [KLOW research](/research) on each mechanism in detail, see the research page.

---

A technical schematic of four separate peer-reviewed literatures — each component dimensioned to its own studies, the untested combination held as the honest blank dimension.